Glycosylation of serum haptoglobin as a marker of gastric cancer: an overview for clinicians

References

• Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018 Nov;68(6):394–424.
   PubMed Web of Science ®Google Scholar
• Matsuoka T, Yashiro M. Biomarkers of gastric cancer: current topics and future perspective. World J Gastroenterol. 2018 July 14;24(26):2818–2832.
   PubMed Web of Science ®Google Scholar
• Duraker N, Naci Celik A, Gencler N. The prognostic significance of gastric juice CA 19-9 and CEA levels in gastric carcinoma patients. Eur J Surg Oncol. 2002 Dec;28(8):844–849.
   PubMedGoogle Scholar
• Kang JM, Kim N, Yoo JY, et al. The role of serum pepsinogen and gastrin test for the detection of gastric cancer in korea. Helicobacter. 2008 Apr;13(2):146–156.
   PubMed Web of Science ®Google Scholar
• Qiu MZ, Lin JZ, Wang ZQ, et al. Cutoff value of carcinoembryonic antigen and carbohydrate antigen 19-9 elevation levels for monitoring recurrence in patients with resectable gastric adenocarcinoma. Int J Biol Markers. 2009 Oct–Dec;24(4):258–264.
   PubMed Web of Science ®Google Scholar
• Takahashi T, Saikawa Y, Kitagawa Y. Gastric cancer: current status of diagnosis and treatment. Cancers (Basel). 2013 Jan 16;5(1):48–63.
   PubMedGoogle Scholar
• Seeberger PH. Exploring life’s sweet spot. Nature. 2005 Oct 27;437(7063):1239.
   PubMed Web of Science ®Google Scholar
• Hua S, Lebrilla C, An HJ. Application of nano-LC-based glycomics towards biomarker discovery. Bioanalysis. 2011 Nov;3(22):2573–2585.
   PubMed Web of Science ®Google Scholar
• Stavenhagen K, Hinneburg H, Thaysen-Andersen M, et al. Quantitative mapping of glycoprotein micro-heterogeneity and macro-heterogeneity: an evaluation of mass spectrometry signal strengths using synthetic peptides and glycopeptides. J Mass Spectrom. 2013 June;48(6):627–639.
   PubMed Web of Science ®Google Scholar
• Baum LG. Developing a taste for sweets. Immunity. 2002 Jan;16(1):5–8.
   PubMed Web of Science ®Google Scholar
• Krasnova L, Wong CH. Understanding the chemistry and biology of glycosylation with glycan synthesis. Annu Rev Biochem. 2016 June 2;85:599–630.
   PubMed Web of Science ®Google Scholar
• Varki A, Kannagi R, Toole B, et al. Glycosylation changes in cancer. In: Varki A, Cummings RD, Esko JD, et al., editors. Essentials of glycobiology. New York (NY): Cold Spring Harbor; 2015. p. 597–609.
   Google Scholar
• Freeze HH. Understanding human glycosylation disorders: biochemistry leads the charge. J Biol Chem. 2013 Mar 8;288(10):6936–6945.
   PubMed Web of Science ®Google Scholar
• Bondt A, Selman MHJ, Deelder AM, et al. Association between galactosylation of immunoglobulin G and improvement of rheumatoid arthritis during pregnancy is independent of sialylation. J Proteome Res. 2013 Oct;12(10):4522–4531.
   PubMed Web of Science ®Google Scholar
• Moremen KW, Tiemeyer M, Nairn AV. Vertebrate protein glycosylation: diversity, synthesis and function. Nat Rev Mol Cell Biol. 2012 June 22;13(7):448–462.
   PubMed Web of Science ®Google Scholar
• Pinho SS, Reis CA. Glycosylation in cancer: mechanisms and clinical implications. Nat Rev Cancer. 2015 Sept;15(9):540–555.
   PubMed Web of Science ®Google Scholar
• Hua S, Williams CC, Dimapasoc LM, et al. Isomer-specific chromatographic profiling yields highly sensitive and specific potential N-glycan biomarkers for epithelial ovarian cancer. J Chromatogr A. 2013 Mar 1;1279:58–67.
   PubMed Web of Science ®Google Scholar
• Hua S, An HJ, Ozcan S, et al. Comprehensive native glycan profiling with isomer separation and quantitation for the discovery of cancer biomarkers. Analyst. 2011 Sept 21;136(18):3663–3671.
   PubMed Web of Science ®Google Scholar
• Ratanasopa K, Chakane S, Ilyas M, et al. Trapping of human hemoglobin by haptoglobin: molecular mechanisms and clinical applications. Antioxid Redox Signal. 2013 June 10;18(17):2364–2374.
   PubMed Web of Science ®Google Scholar
• Kurosky A, Barnett DR, Lee TH, et al. Covalent structure of human haptoglobin: a serine protease homolog. Proc Natl Acad Sci U S A. 1980 June;77(6):3388–3392.
   PubMed Web of Science ®Google Scholar
• Mandato VD, Magnani E, Abrate M, et al. Haptoglobin phenotype and epithelial ovarian cancer. Anticancer Res. 2012 Oct;32(10):4353–4358.
   PubMed Web of Science ®Google Scholar
• Morishita K, Ito N, Koda S, et al. Haptoglobin phenotype is a critical factor in the use of fucosylated haptoglobin for pancreatic cancer diagnosis. Clin Chim Acta. 2018 Dec;487:84–89.
   PubMed Web of Science ®Google Scholar
• Fujita K, Shimomura M, Uemura M, et al. Serum fucosylated haptoglobin as a novel prognostic biomarker predicting high-Gleason prostate cancer. Prostate. 2014 July;74(10):1052–1058.
   PubMed Web of Science ®Google Scholar
• Takahashi S, Sugiyama T, Shimomura M, et al. Site-specific and linkage analyses of fucosylated N-glycans on haptoglobin in sera of patients with various types of cancer: possible implication for the differential diagnosis of cancer. Glycoconj J. 2016 June;33(3):471–482.
   PubMed Web of Science ®Google Scholar
• Arnold JN, Saldova R, Galligan MC, et al. Novel glycan biomarkers for the detection of lung cancer. J Proteome Res. 2011 Apr 1;10(4):1755–1764.
   PubMed Web of Science ®Google Scholar
• Zhang S, Shang S, Li W, et al. Insights on N-glycosylation of human haptoglobin and its association with cancers. Glycobiology. 2016 July;26(7):684–692.
   PubMed Web of Science ®Google Scholar
• Nakano M, Nakagawa T, Ito T, et al. Site-specific analysis of N-glycans on haptoglobin in sera of patients with pancreatic cancer: a novel approach for the development of tumor markers. Int J Cancer. 2008 May 15;122(10):2301–2309.
   PubMed Web of Science ®Google Scholar
• Sarrats A, Saldova R, Pla E, et al. Glycosylation of liver acute-phase proteins in pancreatic cancer and chronic pancreatitis. Proteomics Clin Appl. 2010 4; Apr(4): 432–448.
   Google Scholar
• Park SY, Lee SH, Kawasaki N, et al. alpha1-3/4 fucosylation at Asn 241 of beta-haptoglobin is a novel marker for colon cancer: a combinatorial approach for development of glycan biomarkers. Int J Cancer. 2012 May 15;130(10):2366–2376.
   PubMed Web of Science ®Google Scholar
• Jayanthi M, Habibullah CM, Ishaq M, et al. Distribution of haptoglobin phenotypes in oesophageal and gastric cancer. J Med Genet. 1989 Mar;26(3):172–173.
   PubMed Web of Science ®Google Scholar
• Munoz Navas MA, Amiguet JA, Conchillo F, et al. Haptoglobin in the biological diagnosis of gastric cancer (author’s transl) . Med Clin (Barc). 1980 July 15;75(3):109–111.
   PubMed Web of Science ®Google Scholar
• Bones J, Byrne JC, O’Donoghue N, et al. Glycomic and glycoproteomic analysis of serum from patients with stomach cancer reveals potential markers arising from host defense response mechanisms. J Proteome Res. 2011 Mar 4;10(3):1246–1265.
   PubMed Web of Science ®Google Scholar
• Bones J, Mittermayr S, O’Donoghue N, et al. Ultra performance liquid chromatographic profiling of serum N-glycans for fast and efficient identification of cancer associated alterations in glycosylation. Anal Chem. 2010 Dec 15;82(24):10208–10215.
   PubMed Web of Science ®Google Scholar
• Lee SH, Jeong S, Lee J, et al. Glycomic profiling of targeted serum haptoglobin for gastric cancer using nano LC/MS and LC/MS/MS. Mol Biosyst. 2016 Nov 15;12(12):3611–3621.
   PubMedGoogle Scholar
• Lee J, Hua S, Lee SH, et al. Designation of fingerprint glycopeptides for targeted glycoproteomic analysis of serum haptoglobin: insights into gastric cancer biomarker discovery. Anal Bioanal Chem. 2018 Feb;410(6):1617–1629.
   PubMed Web of Science ®Google Scholar
• Kim JH, Lee SH, Choi S, et al. Direct analysis of aberrant glycosylation on haptoglobin in patients with gastric cancer. Oncotarget. 2017 Feb 14;8(7):11094–11104.
   PubMedGoogle Scholar
• Jimenez CR, Verheul HM. Mass spectrometry-based proteomics: from cancer biology to protein biomarkers, drug targets, and clinical applications. Am Soc Clin Oncol Educ Book. 2014;e504–10. DOI:10.14694/EdBook_AM.2014.34.e504
   PubMedGoogle Scholar
• Miller RA, Spellman DS. Mass spectrometry-based biomarkers in drug development. Adv Exp Med Biol. 2014;806:341–359.
   PubMed Web of Science ®Google Scholar
• Palmblad M, Tiss A, Cramer R. Mass spectrometry in clinical proteomics - from the present to the future. Proteomics Clin Appl. 2009 Jan;3(1):6–17.
   PubMed Web of Science ®Google Scholar
• Aizpurua-Olaizola O, Torano JS, Falcon-Perez JM, et al. Mass spectrometry for glycan biomarker discovery. Trac-Trend Anal Chem. 2018 Mar;100:7–14.
   Web of Science ®Google Scholar
• Asazawa H, Kamada Y, Takeda Y, et al. Serum fucosylated haptoglobin in chronic liver diseases as a potential biomarker of hepatocellular carcinoma development. Clin Chem Lab Med. 2015 Jan;53(1):95–102.
   PubMed Web of Science ®Google Scholar
• Kronewitter SR, An HJ, de Leoz ML, et al. The development of retrosynthetic glycan libraries to profile and classify the human serum N-linked glycome. Proteomics. 2009 June;9(11):2986–2994.
   PubMed Web of Science ®Google Scholar
• Rosen SD, Bertozzi CR. The selectins and their ligands. Curr Opin Cell Biol. 1994 Oct;6(5):663–673.
   PubMed Web of Science ®Google Scholar
• Berg EL, Robinson MK, Mansson O, et al. A carbohydrate domain common to both sialyl Le(a) and sialyl Le(X) is recognized by the endothelial cell leukocyte adhesion molecule ELAM-1. J Biol Chem. 1991 Aug 15;266(23):14869–14872.
   PubMed Web of Science ®Google Scholar
• Kim KH, Kim JY, Yoo JS. Mass spectrometry analysis of glycoprotein biomarkers in human blood of hepatocellular carcinoma. Expert Rev Proteomics. 2019 July;16(7):553–568.
   PubMed Web of Science ®Google Scholar
• Zhu J, Chen Z, Zhang J, et al. Differential quantitative determination of site-specific intact N-glycopeptides in serum haptoglobin between hepatocellular carcinoma and cirrhosis using LC-EThcD-MS/MS. J Proteome Res. 2019 Jan 4;18(1):359–371.
   PubMed Web of Science ®Google Scholar
• Cancilla MT, Wong AW, Voss LR, et al. Fragmentation reactions in the mass spectrometry analysis of neutral oligosaccharides. Anal Chem. 1999 Aug 1;71(15):3206–3218.
   PubMed Web of Science ®Google Scholar
• Hua S, Hu CY, Kim BJ, et al. Glyco-analytical multispecific proteolysis (Glyco-AMP): a simple method for detailed and quantitative Glycoproteomic characterization. J Proteome Res. 2013 Oct 4;12(10):4414–4423.
   PubMed Web of Science ®Google Scholar
• Swaney DL, Wenger CD, Coon JJ. Value of using multiple proteases for large-scale mass spectrometry-based proteomics. J Proteome Res. 2010 Mar 5;9(3):1323–1329.
   PubMed Web of Science ®Google Scholar
• Baerenfaenger M, Meyer B. Intact human alpha-acid glycoprotein analyzed by ESI-qTOF-MS: simultaneous determination of the glycan composition of multiple glycosylation sites. J Proteome Res. 2018 Nov 2;17(11):3693–3703.
   PubMed Web of Science ®Google Scholar
• Loke I, Packer NH, Thaysen-Andersen M. Complementary LC-MS/MS-Based N-Glycan, N-Glycopeptide, and Intact N-Glycoprotein Profiling reveals unconventional Asn71-Glycosylation of human neutrophil Cathepsin G. Biomolecules. 2015 Aug 12;5(3):1832–1854.
   PubMed Web of Science ®Google Scholar
• Behnken HN, Ruthenbeck A, Schulz JM, et al. Glycan analysis of Prostate Specific Antigen (PSA) directly from the intact glycoprotein by HR-ESI/TOF-MS. J Proteome Res. 2014 Feb 7;13(2):997–1001.
   PubMed Web of Science ®Google Scholar
• Harazono A, Hashii N, Kuribayashi R, et al. Mass spectrometric glycoform profiling of the innovator and biosimilar erythropoietin and darbepoetin by LC/ESI-MS. J Pharm Biomed Anal. 2013 Sept;83:65–74.
   PubMed Web of Science ®Google Scholar
• Baerenfaenger M, Meyer B. Simultaneous characterization of SNPs and N-glycans from multiple glycosylation sites of intact beta-2-glycoprotein-1 (B2GP1) by ESI-qTOF-MS. Biochim Biophys Acta Proteins Proteom. 2019 June;1867(6):556–564.
   PubMed Web of Science ®Google Scholar
• Jungblut PR, Holzhutter HG, Apweiler R, et al. The speciation of the proteome. Chem Cent J. 2008 July 18;2:16.
   PubMed Web of Science ®Google Scholar
• Tran JC, Zamdborg L, Ahlf DR, et al. Mapping intact protein isoforms in discovery mode using top-down proteomics. Nature. 2011 Dec 8;480(7376):254–U141.
   PubMed Web of Science ®Google Scholar